OMCL

+ Watchlist + Portfolio

Omnicell, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $35.50
52-Week Range: $29.06 – $55.00
Market Cap: $1.61B
P/E (TTM): 42.15
EPS (TTM): 0.84
Dividend Yield: —

Advanced Metrics

Price/Book: 1.25
PEG Ratio: 15.40
Return on Equity: 3.06%
Return on Assets: 1.94%
Gross Margin: 45.14%
Operating Margin: 10.39%
Profit Margin: 3.14%
Current Ratio: 1.64
Debt/Equity: 0.15
Total Debt: $200.00M
Free Cash Flow: $142.93M
Revenue Growth: 7.50%
Earnings Growth: 333.30%
Enterprise Value: $1.53B

OMCL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.30B	$1.15B	$1.11B	$1.18B
Cost of Revenue	$706.96M	$650.27M	$641.24M	$681.40M
Gross Profit	$588.99M	$496.84M	$471.00M	$503.44M
Research & Development	$104.97M	$97.11M	$90.41M	$88.67M
Selling, General & Admin	$486.34M	$434.59M	$380.25M	$409.61M
Operating Expenses	$591.31M	$531.71M	$470.67M	$498.28M
Operating Income	-$2.32M	-$34.87M	$337.00K	$5.16M
EBITDA	$96.85M	$60.69M	$90.09M	$91.79M
Pretax Income	-$2.45M	-$20.11M	$25.59M	$11.32M
Income Tax	-$8.10M	$263.00K	$13.06M	$9.27M
Net Income	$5.65M	-$20.37M	$12.53M	$2.05M
Diluted EPS	0.12	-0.45	0.27	0.04
Diluted Shares	45.89M	45.21M	46.26M	46.36M

OMCL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$330.36M	$467.97M	$369.20M	$196.52M
Receivables	$299.47M	$252.03M	$256.40M	$216.86M
Inventory	$147.55M	$110.10M	$88.66M	$100.91M
Current Assets	$881.81M	$927.57M	$815.49M	$680.07M
Total Assets	$2.21B	$2.23B	$2.12B	$1.97B
Current Liabilities	$428.45M	$367.79M	$595.68M	$476.61M
Long-Term Debt	$566.57M	$569.66M	$166.40M	$167.60M
Total Debt	$616.74M	$614.09M	$382.55M	$204.34M
Total Liabilities	$1.08B	$1.04B	$877.65M	$742.91M
Retained Earnings	$390.73M	$370.36M	$382.89M	$384.94M
Shareholders' Equity	$1.13B	$1.19B	$1.24B	$1.23B
Working Capital	$453.37M	$559.78M	$219.81M	$203.46M
Net Debt	$236.21M	$101.69M	—	—

OMCL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$77.78M	$181.09M	$187.72M	$127.30M
Capital Expenditure	-$60.74M	-$55.02M	-$52.79M	-$57.93M
Free Cash Flow	$17.04M	$126.08M	$134.93M	$69.37M
Depreciation & Amortisation	$99.17M	$95.56M	$89.75M	$86.63M
Stock-Based Compensation	$68.25M	$55.30M	$39.32M	$44.50M
Investing Cash Flow	-$58.67M	-$55.02M	-$52.79M	-$60.36M
Financing Cash Flow	-$20.95M	$23.42M	-$235.58M	-$218.32M
Share Repurchases	-$52.21M	$0.00	$0.00	-$77.60M
Net Change in Cash	-$1.84M	$149.50M	-$100.65M	-$151.38M

OMCL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$269.67M	$290.56M	$310.63M	$313.98M	$309.88M
Cost of Revenue	$158.73M	$162.88M	$176.13M	$183.66M	$169.52M
Gross Profit	$110.94M	$127.68M	$134.50M	$130.32M	$140.36M
Research & Development	$20.53M	$21.57M	$24.02M	$22.55M	$21.52M
Selling, General & Admin	$102.03M	$97.98M	$102.24M	$107.36M	$101.99M
Operating Expenses	$122.56M	$119.56M	$126.26M	$129.91M	$123.51M
Operating Income	-$11.62M	$8.12M	$8.24M	$415.00K	$16.85M
EBITDA	$10.22M	$29.77M	$29.61M	$22.20M	$37.35M
Pretax Income	-$9.53M	$10.45M	$9.70M	$699.00K	$16.91M
Income Tax	-$2.51M	$4.81M	$4.24M	$2.73M	$5.55M
Net Income	-$7.02M	$5.64M	$5.46M	-$2.03M	$11.36M
Diluted EPS	-0.15	0.12	0.12	-0.05	0.25
Diluted Shares	46.60M	46.99M	45.90M	44.96M	45.94M

OMCL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$386.83M	$399.00M	$180.05M	$196.52M	$239.22M
Receivables	$251.60M	$232.68M	$245.72M	$216.86M	$249.80M
Inventory	$91.14M	$105.78M	$107.43M	$100.91M	$99.20M
Current Assets	$839.67M	$844.78M	$659.62M	$680.07M	$722.30M
Total Assets	$2.15B	$2.15B	$1.95B	$1.97B	$2.00B
Current Liabilities	$607.53M	$594.39M	$456.59M	$476.61M	$483.05M
Long-Term Debt	$166.70M	$166.99M	$167.29M	$167.60M	$167.90M
Total Debt	$385.83M	$384.41M	$206.78M	$204.34M	$202.18M
Total Liabilities	$894.37M	$881.88M	$727.70M	$742.91M	$747.48M
Retained Earnings	$375.87M	$381.50M	$386.97M	$384.94M	$396.30M
Shareholders' Equity	$1.26B	$1.26B	$1.22B	$1.23B	$1.26B
Working Capital	$232.13M	$250.38M	$203.03M	$203.46M	$239.25M

OMCL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$25.92M	$42.76M	$28.27M	$30.35M	$54.50M
Capital Expenditure	-$15.74M	-$15.92M	-$14.28M	-$11.99M	-$15.87M
Free Cash Flow	$10.19M	$26.83M	$13.99M	$18.36M	$38.63M
Depreciation & Amortisation	$21.84M	$21.65M	$21.36M	$21.78M	$20.50M
Stock-Based Compensation	$10.79M	$10.53M	$11.21M	$11.98M	$9.50M
Investing Cash Flow	-$15.74M	-$15.92M	-$14.28M	-$14.42M	-$15.87M
Financing Cash Flow	$4.04M	-$11.47M	-$219.98M	$9.10M	$2.39M
Share Repurchases	—	—	-$61.95M	$0.00	—
Net Change in Cash	$14.22M	$15.36M	-$206.00M	$25.03M	$41.02M

Market Snapshot

About

Omnicell provides automation and analytics solutions for hospital medication management. The company's products include automated dispensing cabinets, IV compounding robots, medication adherence packaging, and inventory management software. Omnicell's systems help hospitals reduce medication errors, control costs, and improve workflow efficiency.